MANDARINE GLOBAL MICROCAP R Global Microcaps ISIN LU1329694266

M	A	Ν
D	A	R
i	Ν	E

MONTHLY REPORT AUGUST 29, 2025

Risk profile 1 2 3 4 5 6 7 +4.2% +8.5% 16.0% Performance Performance YTD Volatility 1 month 1 vea Bench. Bench Bench +44% +8.9% 154%

Augustin LECOQ Théo COLOMBANI

The global markets continued to gain ground in August, buoyed by up by a generally solid reporting season. An improving trade situation, with Washington and Beijing extending their tariff ceasefire, and a meeting held between Donald Trump and Volodymyr Zelensky left Europe feeling more upbeat. In the USA, meanwhile, optimism was fuelled by Jerome Powell's Jackson Hole speech which was deemed to be accommodative, suggesting that interest rates might possibly be cut in September.

The MSCI World index gained +0.3% over the month, the MSCI World Smallcap index +2.8% and the MSCI World Microcap index +4.4%. The fund slightly underperformed its benchmark index, with 106 of its 320 names losing ground. Its top contributors included LIQUIDIA (+57%), which continued to enjoy excellent momentum thanks to expectations surrounding its new product, as well as BK TECHNOLOGIES (+86%) and INFUSYSTEM (+87%), which both stood out by delivering earnings well above expectations. On the other hand, the earnings reported by MYOMO (-45%) and VIANT TECHNOLOGY (-29%) missed expectations and they were withdrawn from the portfolio as their GARP profiles have deteriorated; and SENSUS HEALTHCARE (-40%) was penalised by recent limits imposed on the reimbursement of its products. The main portfolio movements included our decision to sell off our shares in YONEX, VAULT MINERALS and LIQUIDIA, whose market capitalisations now exceed our €2bn threshold, and in YICHANG HEC, following its takeover by Sunshine Lake Pharma. Meanwhile, we initiated positions in BASLER, a leading developer of industrial vision solutions; AMERESCO, a US firm specialising in energy efficiency and renewable energy solutions; and OPTEX, a Japanese designer of sensors and detection systems for security and automation, as we believe they offer attractive GARP profiles.

Main transactions over the month

	(-) vault minerals (-) yonex (-) liquidia
(+) New holding (-) Sale	

Major contributors/detractors over the month (%)				
LIQUIDIA CORP +0.4	MYOMO INC -0.4			
BK TECHNOLOGIES +0.3	VIANT TECHNOLOG0.1			
INFUSYSTEM HOLD +0.2	SFC ENERGY AG-BR -0.1			

Mandarine Global Microcap invests in the smallest global market capitalisations, applying a quantitative screening filter followed by fundamental stock analysis, designed to detect those stocks which offer the most favourable risk/return profile.

Market Performances and Risks

The data presented relates to past periods, past performance is not an indicator of future results. Statistical indicators are calculated on a weekly basis. Benchmark: MSCI World Microcap NR EUR







Rolling / annualized performances

Rolling performances					Annual	ized perfor	mance		
	1 month	YTD	1 year	3 years	5 years	Inception	3 years	5 years	Inception
Fund	+4.2%	+8.5%	+14.6%	+21.3%	+59.2%	+106.7%	+6.7%	+9.7%	+8.3%
Bench.	+4.4%	+8.9%	+15.3%	+16.1%	+57.0%	+98.5%	+5.1%	+9.4%	+7.8%
Diff.	-0.1%	-0.4%	-0.7%	+5.2%	+2.2%	+8.2%	+1.6%	+0.3%	+0.5%
Quartile*	1	2	1	3	2	2			

EAA Fund Global Small/Mid-Cap Equity

Risk indicators

	Fund volatility	Benchmark volatility	Tracking error	Information ratio	Sharpe ratio
1 year	16.0%	15.4%	3.6%	-0.1	0.8
\$ 3 years	13.4%	13.0%	3.3%	0.4	0.2

MANDARINE GLOBAL MICROCAP R



PORTFOLIO STRUCTURE

Main holdings

WASION HOLDINGS LTD	0.5%	Technology / Hong Kong
INTEGRA RESOURCES CORP	0.5%	Materials / Canada
VAULT MINERALS LTD	0.5%	Materials / Australia
PANTORO LTD	0.5%	Materials / Australia
GENUSPLUS GROUP LTD	0.5%	Industrials / Australia
SRG GLOBAL LTD	0.5%	Industrials / Australia
MAX STOCK LTD	0.5%	Cons.Discretionary / Israel
REZOLUTE INC	0.5%	Health Care / United-States
VITAL FARMS INC	0.5%	Cons.Staples / United-States
UNITY BANCORP INC	0.5%	Financials / United-States

Sector 🧧	Country
Industrials 21.3%	Japan
Technology 16.4%	United-Sta
Financials 14.2%	Australia
Health Care 11.7%	Great Brita
Cons.Discretionary 9.7%	Canada
Materials 7.5%	Sweden
Cons.Staples 4.5%	Israel
Communication serv. 4.3%	Norway
Real Estate 3.9%	China
Energy 3.0%	Singapore
Utilities 0.3%	Germany
Cash & Others 3.2%	France

ntry 📒 28.2% d-States 25.0% 7.7% alia 7.2% Britain da 5.4% en ay

Italy Other Country Cash & Others

4.2%	
3.7%	
1.7%	
1.5%	
1.4%	
1.4%	
1.3%	
1.2%	
6.1%	
3.2%	

FUND PROFILE \odot

res at August 29 2025 📒		Capitalisation	
inder management	27.6M€		·
/ exposure	96.7%		
iber of holdings	320		
ive share	93.7%		
erage capitalisation (Bln €)	0.53		
PS growth (Next 12 M./Last 12 M.)	+11.6%		
E (Next 12 Months)	13.4x	> 500 mln € 44.0%	JPY 28
SG profile 📕		300-500 mln € 25.3%	USD 27
		150-300 mln € 18.5%	EUR
Bench.		NA 1.2%	GBP
Carbon footprint 0		< 150 mln € 7.7%	AUD
Tonnes of CO2e/M€ invested. Direct (scope 1-2) + Fi	rst tier indirect	Cash & Others 3.2%	Other Currency 20

CHARACTERISTICS (III)

10

Mandarine Gestion 30 avenue Kléber | 75016 Paris www.mandarine-gestion.com

f

. .

in

ISIN	Bloomberg code	Inception of the fund	Shareclass inception 12/07/2016
LU1329694266	MGMCRAE LX Equity	12/07/2016	
Legal Status	Shareclass currency	Investment horizon	Management company
Sicav Lux.	EUR	5 years	Mandarine Gestion
Depositary	Valuation	Cut-Off	Settlement
BNP Paribas	Daily	13h00	D+3
Management Fee 1.95%	Performance Fee 20% of the outperformance over the benchmark	Initial charge 2.00%	Redemption Fee 0%

DISCLAIMER The purpose of this document is to present, for information purposes only, the characteristics of Mandarine Gestion products. It in no manner constitutes a sale or subscription offer. The indices cited in this document are based on net dividends reinvested ("NR"). The described performances do not take into account fees and costs potentially charged in connection with the subscription or redemption of fund units. This document has been drawn up for information purposes only and does not constitute an offer or personalised recommendation or a solicitation to subscribe to this product. The information opinions and analyses contained in this document do not have any contractual value. Only the information contained in the KIID and prospectus is legally binding. The prospectus is available on simple demand from Mandarine Gestion and is available on the www.mandarine-gestion.com website. Your money will be principally invested in financial instruments selected by the management company. These instruments will be subject to market fluctuations and uncertainties. Past performances do not guarantee future performances. Performances do not dust in the issue and over time. The performance data mentioned in the document does not take into account fees and charges assessed in connection with the issue and redemption of units or shares and does not include taxes imposed by the country of residence of the cilent. The UCITS is registered are not authorised.

sale to residents of those countries in which the UCITS is registered. Sales in jurisdictions other than those countries in which the UCITS is registered are not authorised. RISK PROFILE – RISKS ASSOCIATED WITH THE PRODUCT Risk of capital loss, equity market risk, risk linked to the ownership of small and midcaps, interest rate risk, credit risk and discretionary management risk, and to a lesser extent emerging market risk, counterparty risk and exchange rate risk. The descriptions and details are included in the complete prospectus of the UCITS. Investors are invited to read the prospectus in order to obtain detailed information regarding the risks to which the fund is exposed prior to any investment decision. This product does not offer any guarantee as to returns or the capital invested, which may not be entirely returned.